通化金马股价涨5.03%，国联安基金旗下1只基金重仓，持有9.68万股浮盈赚取12.2万元

Group 1 - The core viewpoint of the news is the performance and financial metrics of Tonghua Jinma Pharmaceutical Group Co., Ltd, highlighting its stock price increase and market capitalization [1] - As of September 11, Tonghua Jinma's stock rose by 5.03%, reaching a price of 26.29 yuan per share, with a trading volume of 1.584 billion yuan and a turnover rate of 6.61%, resulting in a total market value of 25.409 billion yuan [1] - The company, established on February 26, 1993, and listed on April 30, 1997, focuses on the research, production, and sales of pharmaceuticals, with its main revenue sources being biopharmaceuticals (59.27%), traditional Chinese medicine (40.56%), raw materials (0.10%), and others (0.07%) [1] Group 2 - From the perspective of fund holdings, Guolian An Fund has a significant position in Tonghua Jinma, with its Guolian An CSI Pharmaceutical 100A fund holding 96,800 shares, accounting for 1.04% of the fund's net value [2] - The fund reduced its holdings by 47,600 shares in the second quarter, and the estimated floating profit from this investment is approximately 122,000 yuan [2] - The Guolian An CSI Pharmaceutical 100A fund, established on August 21, 2013, has a current scale of 178 million yuan, with a year-to-date return of 20.34% and a one-year return of 38.85% [2]